October 10, 2015
NATIONAL HARBOR, Md — In this video, James Januzzi, MD, professor of medicine at Harvard Medical School and cardiologist at Massachusetts General Hospital, provides an overview of data on combination therapy with an angiotensin receptor blocker and a neprilisyn inhibitor presented at the Heart Failure Society of America Annual Scientific Meeting.
The combination of sacubitril and valsartan (Entresto, Novartis) is approved for treatment of patients with HF and reduced ejection fraction. This approval followed results from the PARADIGM-HF trial, which indicated a 20% reduction in CV-related death and HF-related hospitalization compared with enalapril, Januzzi said. Retrospective data from PARADIGM-HF presented at HFSA indicated improved stabilization of patients with regard to NT-proBNP measurements when treated with sacubitril/valsartan compared with enalapril. “It really does appear to be a major advance forward for HF therapeutics,” Januzzi said.